Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004.

OBJECTIVE: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. METHODS: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Medical Research & Opinion Vol. 25; no. 7; pp. 1605 - 1614
Autores principales: Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR
Formato: research tables/charts Journal Article
Publicado: Taylor & Francis Ltd Jul2009
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105432887&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105432887
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03007995
        DFY
      jtl: Current Medical Research & Opinion
      issn: 03007995
      maglogo: N
    pubinfo:
      dt: Jul2009
      vid: 25
      iid: 7
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        105432887
        105432887
        2010390903
        10.1185/03007990902973300
        NLM19469695
        105432887
      ppf: 1605
      ppct: 9
      formats:
      tig:
        atl: Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004.
      aug:
        au:
          Dodd AH
          Colby MS
          Boye KS
          Fahlman C
          Kim S
          Briefel RR
        affil: Mathematica Policy Research, Inc., Washington, DC 20024-2512, USA. adodd@mathematica-mpr.com
      sug:
        subj:
          Diabetes Mellitus, Type 2 Drug Therapy
          Diabetes Mellitus, Type 2 Prevention and Control
          Glycemic Control
          Administration, Oral
          Adult
          Aged
          American Diabetes Association
          Data Analysis Software
          Drug Therapy, Combination
          Female
          Funding Source
          Glycated Hemoglobin Blood
          Male
          Metformin Therapeutic Use
          Middle Age
          Practice Guidelines
          Sulfonylurea Compounds Therapeutic Use
          T-Tests
          Thiazolidinediones Therapeutic Use
          Treatment Outcomes
          Human
          Adult: 19-44 years
          Aged: 65+ years
          Middle Aged: 45-64 years
          Female
          Male
      ab: OBJECTIVE: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. METHODS: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were used to determine the treatment approach for US adults with type 2 diabetes. Mean glycosylated hemoglobin (HbA1c) and the proportion of adults meeting recommended guidelines for glucose control were estimated for each treatment approach. The most important study limitation was that participants were not asked what type of diabetes they had. Among adults with diabetes, a classification algorithm was used to identify those with type 2 diabetes. RESULTS: During 1999-2004, approximately 60% of adults with type 2 diabetes used oral agents only to manage their diabetes. The distribution of oral treatment therapies changed over time (p < 0.01); the most prevalent treatment shifted from sulfonylurea monotherapy in 1999-2000 (23.0%) to any oral agent regimen containing thiazolidinedione (TZD) in 2003-2004 (21.4%). Overall, only 52.2% of adults with type 2 diabetes met the American Diabetes Association (ADA) goal for HbA1c control (<7.0%) during 1999-2004. Across oral agent treatment categories, the proportion with HbA1c controlled at the 7.0 level was significantly lower (p < 0.01) for those on triple therapy (31.9%) (TZD, sulfonylurea, and metformin), than those on metformin alone (62.2%), likely reflecting a progressive treatment approach of prescribing additional medications for those with uncontrolled HbA1c levels. CONCLUSIONS: Use of multiple oral agents among adults with type 2 diabetes has increased (sulfonylurea and metformin, p = 0.03, triple therapy, p = 0.02). However, nearly half of adults with type 2 diabetes have HbA1c levels above ADA guidelines for control, indicating that available treatments could be used more optimally, and new diabetic agents may be needed.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N